{
    "clinical_study": {
        "@rank": "126218", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Filter", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo device"
            }, 
            {
                "arm_group_label": "Rhinix Nasal Filter", 
                "arm_group_type": "Active Comparator", 
                "description": "Actual Rhinix Nasal Filter"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the effects of RHINIX\u2122 nasal filters on seasonal allergic rhinitis\n      (hay fever) in a park setting."
        }, 
        "brief_title": "Efficacy Park Study Assessing Rhinix\u2122 Nasal Filters for Hay Fever", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will include 100 participants with grass allergy and will look at the efficacy and\n      usability of RHINIX\u2122 nasal filters on hay fever in a randomized, double-blind,\n      placebo-controlled, crossover design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of seasonal allergic rhinitis (SAR) for a minimum of 2 years before study\n             entry. Documented by a positive skin test (wheal > 3mm) within 12 months of study\n             enrolment.\n\n          -  Written informed consent\n\n          -  Must be able to complete the study\n\n          -  Reliable anticonception for fertile women\n\n          -  FEV1 higher than 70 % of predicted value\n\n          -  Positive grass IgE blood sample higher or equal to 0,7 kU/L\n\n        Exclusion Criteria:\n\n          -  Improper fit of the Rhinix\u2122 device\n\n          -  Nasal septal deviation\n\n          -  Retrospective TNSS for last summer < 3\n\n          -  Positive pregnancy test for fertile women\n\n          -  Inadequate washout periods in regards to park study appointments (intranasal or\n             systemic corticosteroids (1month), intranasal cromolyn (2 weeks), intranasal or\n             systemic decongestants (3 days), intranasal or systemic antihistamines (3 days),\n             Loratadine (10 days)).\n\n          -  Rhinitis medicamentosa\n\n          -  Use of long acting anti-histamines.\n\n          -  Documented evidence of acute or cronic sinusitis, as determined by the individual\n             investigator.\n\n          -  FEV1 lower than 70 % of predicted value\n\n          -  Subjects with nasal conditions likely to affect the outcome of the study in the\n             opinion of the investigator, i.e. anterior nasal septum deviation, nasal septal\n             perforations, nasal polyps, chronic nasal obstruction or other nasal diseases.\n\n          -  Receipt of immunotherapy with grass pollen within the previous 10 years (at least two\n             rounds of treatment).\n\n          -  Women who are breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108574", 
            "org_study_id": "1401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo Filter", 
                "intervention_name": "Placebo Filter", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Rhinix Nasal Filter", 
                "intervention_name": "Rhinix Nasal Filter", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "ptkh@mil.au.dk", 
                "last_name": "Peter S Kenney"
            }, 
            "facility": {
                "address": {
                    "city": "Aarhus C", 
                    "country": "Denmark", 
                    "zip": "8000"
                }, 
                "name": "Aarhus University, School of Public Health, Department of Environmental & Occupational Medicine"
            }, 
            "investigator": {
                "last_name": "Torben Sigsgaard, Prof. MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Placebo-controlled, Randomized Single-centre Crossover Park Study Assessing Rhinix\u2122 Nasal Filters", 
        "overall_contact": {
            "email": "ts@mil.au.dk", 
            "last_name": "Torben Sigsgaard, Prof. MD. PhD", 
            "phone": "+4587168013"
        }, 
        "overall_contact_backup": {
            "email": "ptkh@mil.au.dk", 
            "last_name": "Peter S. Kenney, MD-PhD Student"
        }, 
        "overall_official": {
            "affiliation": "Aarhus University, School of Public Health, Dept. of Environmental & Occupational Medicine", 
            "last_name": "Torben Sigsgaard, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: The Regional Committee on Biomedical Research Ethics", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Baseline recording at 09.00 Run-in recordings from 09.30-11.00 Daily Total Nasal Symptom Score evaluated from 11.00-17.00 with the last recording at 17.00, recordings at 30 minute increments.\nTotal Nasal Symptom Score is the sum of 4 symptoms (runny nose, blocked nose, itchy nose and sneezing) which are each evaluated on a scale of 0=none, 1=mild, 2=moderate, 3=severe symptoms", 
            "measure": "To assess the change in daily Total Nasal Symptom Score (TNSS) between Rhinix\u2122 and placebo", 
            "safety_issue": "No", 
            "time_frame": "11.00-17.00 with recordings at 30. minute increments."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108574"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Baseline recording at 09.00 Run-in recording at. 10.00 Daily Throat Irritation evaluated from 11.00-17.00 with the last recording at 17.00, recordings at hourly increments.\nDaily Throat Irritation is the sum of 6 symptom ratings on a Visual Analogue Scale.", 
                "measure": "To assess the change in Daily Throat Irritation between Rhinix\u2122 and placebo", 
                "safety_issue": "No", 
                "time_frame": "11.00-17.00 with hourly increments"
            }, 
            {
                "description": "Daily TNSS is described in the Primary Efficacy Endpoint. Maximum TNSS is the single highest TNSS between 11.00 and 17.00\nThe correlation will be graphically shown using a Bland-Altman plot.", 
                "measure": "To assess the correlation between maximum TNSS and difference in Daily TNSS", 
                "safety_issue": "No", 
                "time_frame": "11.00-17.00 at 30 minute increments"
            }, 
            {
                "description": "Subgroup analysis of change in daily TNSS between RHINIX and placebo for the subjects with at least one rating of TNSS \u2265 6 on at least one of the two study days.\nSee primary outcome measure for more details.", 
                "measure": "Change in Daily TNSS for subgroup", 
                "safety_issue": "No", 
                "time_frame": "11.00-17.00 at 30 minute increments"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "collaborator": {
                "agency": "Rhinix ApS", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}